A Prospective Clinical Study to Evaluate the Effectiveness and Safety of Xcell Amnio MatrixTM (XAM) in the Management of Different Wound Types

Not Applicable

Not yet recruiting

• Conditions: Diabetic Foot Ulcer (DFU); Venous Leg Ulcer (VLU); Post-Mohs Surgical Wound
• Interventions: Biological: Xcell Amnio Matrix

• Registration Number: NCT07116174
• Lead Sponsor: New Horizon Medical Solutions

Brief Summary

The goal of this clinical trial is to evaluate the clinical outcomes of various wound types (DFUs, VLUs, and post-Mohs surgery) treated with a weekly application of Xcell Amnio MatrixTM (XAM) as adjunct to standard of care (SOC) in male and female over the age of 18 years old. The main question it aims to answer is:

What percentage of wound area will change during the 12 weeks of the treatment phase?

Participants:

* Will be screened and re-screened after 2 weeks to be assessed whether they meet the eligibility criteria

* Eligible subjects will receive study product application, and for 12 weeks will return to the clinic once every 7 days (±3 days) for treatment visits

* Subjects who complete the treatment will be followed up after 2 weeks

Detailed Description

Not available

Study Timeline

• Status Verified: 2025-07
• Study First Submitted: 2025-07-25
• Study First Submitted QC: 2025-08-04
• Last Update Submitted: 2025-08-04
• Study First Posted: 2025-08-11
• Last Update Posted: 2025-08-11
• Study Start: 2025-08-15
• Primary Completion: 2026-08-15
• Study Completion: 2026-08-15

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

Subjects will be eligible for enrollment in the study only if they meet ALL the following criteria at time of Screening:

1. Subject is 18 years of age or older.

2. For subjects with DFU:

   1. Subject has diabetes mellitus (Type 1 or Type 2), requiring insulin or oral/injectable medications to control blood glucose levels

   2. Glycosylated hemoglobin (HbA1c) level is <12%

      Note: Prior documented HbA1c within 12 weeks of Screening is acceptable.

   3. Duration of ulcer is ≥ 4 weeks but ≤ 1 year, unresponsive to SOC

   4. Ulcer area is ≥ 1.5cm2 and ≤ 20cm2 and with a clean, granulating base with minimal adherent slough at the Baseline Visit

   5. Ulcer location is at or below the ankle (malleolus)

   6. Subject is amenable to use of off-loading, as needed for planter ulcer

   7. Ulcer extends through the full thickness of the skin but not down to muscle, tendon, or bone

   OR, For subjects with VLU:

   1. Subject with ulcer primarily caused by venous insufficiency
   2. Duration of ulcer is ≥ 4 weeks but ≤ 1 year, unresponsive to SOC
   3. Ulcer area is ≥ 1.5cm2 and ≤ 20cm2 and with a clean, granulating base with minimal adherent slough at the Baseline Visit
   4. Ulcer location is at or above the ankle (malleolus) and below the knee
   5. Ulcer location is appropriate for use of compression therapy treatment
   6. Ulcer extends through the full thickness of the skin but not down to muscle, tendon, or bone

   OR, For subjects with post-operative defects after Mohs surgery

   a. ≥6 mm (in greatest diameter or length of circular or oval geometric shape) at the Baseline Visit

3. Subject is at least 12 weeks post lower extremity revascularization procedure, if one has been performed.

4. Subject is in general good health, with no clinically significant medical conditions or abnormalities that, in the opinion of the Investigator, would interfere with study participation, the assessment of study endpoints, or pose additional risk to the subject.

5. Adequate circulation to the affected lower extremities as demonstrated by one of the following within 12 weeks of screening:

   1. Dorsum transcutaneous oxygen measurement (TCOM) ≥ 30 mmHg,
   2. Skin perfusion pressure (SPP) measurement ≥ 30 mmHg,
   3. Ankle-Brachial Index (ABI) ≥0.7 and ≤1.2, OR
   4. Toe-Brachial Index (TBI) ≥ 0.6

6. Subject is willing to use an acceptable method of contraception throughout the duration of the trial, if of childbearing potential.

   Acceptable methods of contraception include abstinence, female subject/partner's use of hormonal contraceptive (oral, patch, injectable, depot or vaginal) in conjunction with a barrier method (e.g., diaphragm, cervical cap, condom, spermicide or sponge), or female subject/partner's use of an implantable device (implantable rod or intrauterine device).

   Female subject/partners of non-childbearing potential are defined as surgically sterile (e.g., bilateral tubal ligation, hysterectomy) or two years postmenopausal at time of screening.

   All male subjects (excluding men who have been sterilized) with female partners of child-bearing potential must agree to consistently and correctly use a condom for the duration of the study. In addition, subjects may not donate sperm for the same time period.

7. Subject is able to read, understand and sign the informed consent form (ICF).

8. Subject is available and willing to complete all study assessments and can comply with standard of care (debridement, dressing changes etc.) as applicable.

Exclusion Criteria

Subjects meeting ANY of the following criteria at time of Screening will be excluded from enrollment:

All subjects:

1. Clinical evidence of ongoing infection and/or receipt of IV, oral, or topical antimicrobials.

2. Wheelchair bound or bed-ridden (ambulatory with assistance is acceptable).

3. Ulceration at the site of amputation.

4. Undergoing renal dialysis.

5. Known or suspected malignancy in the target ulcer, or a history of cancer in the preceding 5 years (other than carcinoma in situ of the cervix or adequately treated non-melanoma skin cancer).

6. Documented history of osteomyelitis at the target ulcer location within 6 months of screening.

7. History of radiation at the ulcer site.

8. New York Heart Association Class III or IV congestive heart failure or uncontrolled cardiac dysrhythmia.

9. Diagnosis of autoimmune disease(s) (rheumatoid arthritis, lupus, psoriasis, Sjogren's syndrome) or arthritis requiring corticosteroid treatment.

10. Subject has received in the past 4 weeks or is scheduled to receive any of following medication or therapies during the course of the study:

    1. Immunosuppressants (including chronic systemic corticosteroids or application of topical steroids to the ulcer surface)
    2. Cytotoxic chemotherapy
    3. Growth hormone
    4. Oral or systemic antifungal or antituberculosis treatment
    5. Use of any investigational drug(s) or therapeutic device(s)

11. Target ulcer(s) previously treated with negative pressure, hyperbaric oxygen, or tissue engineered materials (eg, Apligraf®, EpiFix® or Dermagraft®) or other scaffold materials (eg, Oasis, Matristem) within 4 weeks prior to screening.

12. Target ulcer(s) anticipated to require negative pressure wound therapy or hyperbaric oxygen at any time during the study.

13. Healing of target ulcer is observed to be ≥35% at the end of the Run-in Period (between Screening and Baseline Visits)

14. Subject is pregnant or breastfeeding.

15. Presence of any other condition(s) which seriously compromises the subject's ability to complete this study, or has a known history of poor adherence with medical treatment.

    For subjects with DFU:

16. Active Charcot foot (stable chronic Charcot foot is not exclusionary).

17. Ulcers on toes 2, 3, 4, and/or 5 only (ulcer on plantar surface of the great toe only is not exclusionary).

    For subjects with VLU:

18. Deep vein thrombosis diagnosed within 4 weeks prior to screening.

19. Refusal or inability to tolerate compression therapy.

    For subjects with post-Mohs surgery wounds:

20. Wounds on the head, neck or digits.

21. Subjects in which primary linear closure is recommended.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
subjects with wounds (Diabetic Foot Ulcer, Venous Leg Ulcer, post-Mohs surgical wound)	Xcell Amnio Matrix	-

Primary Outcome Measures

Name	Time	Method
Wound Area Change (%) during the 12 weeks of the Treatment Phase	Baseline to12 weeks	Wound area change is defined as the percentage of wound area change as measured by wound imaging device.

Secondary Outcome Measures

Name	Time	Method
Proportion of subjects with complete wound closure during the 12 weeks of the Treatment Phase	Baseline to 12 weeks	Complete wound closure is defined as 100% re-epithelialization without drainage or dressing requirements confirmed at two consecutive study visits 2 weeks apart.
Time to complete wound closure during the 12 weeks of the Treatment Phase	Baseline to 12 weeks	The time of complete closure will be the visit when 100% re-epithelialization without drainage or dressing requirements was first achieved.